Michael S Hildebrand1, Candace T Myers1, Gemma L Carvill1, Brigid M Regan1, John A Damiano1, Saul A Mullen1, Mark R Newton1, Umesh Nair1, Elena V Gazina1, Carol J Milligan1, Christopher A Reid1, Steven Petrou1, Ingrid E Scheffer1, Samuel F Berkovic2, Heather C Mefford2. 1. From the Epilepsy Research Centre (M.S.H., B.M.R., J.A.D., S.A.M., M.R.N., I.E.S., S.F.B.), Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia; Division of Genetic Medicine (C.T.M., G.L.C., H.C.M.), Department of Pediatrics, University of Washington, Seattle, WA; Florey Institute for Neuroscience and Mental Health (U.N., E.V.G., C.J.M., C.A.R., S.P., I.E.S.), University of Melbourne, Melbourne, Victoria, Australia; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia; and Department of Pediatrics (I.E.S.), University of Melbourne, Royal Children's Hospital, Melbourne, Victoria, Australia. 2. From the Epilepsy Research Centre (M.S.H., B.M.R., J.A.D., S.A.M., M.R.N., I.E.S., S.F.B.), Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia; Division of Genetic Medicine (C.T.M., G.L.C., H.C.M.), Department of Pediatrics, University of Washington, Seattle, WA; Florey Institute for Neuroscience and Mental Health (U.N., E.V.G., C.J.M., C.A.R., S.P., I.E.S.), University of Melbourne, Melbourne, Victoria, Australia; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia; and Department of Pediatrics (I.E.S.), University of Melbourne, Royal Children's Hospital, Melbourne, Victoria, Australia. hmefford@uw.edu s.berkovic@unimelb.edu.au.
Abstract
OBJECTIVES: We report development of a targeted resequencing gene panel for focal epilepsy, the most prevalent phenotypic group of the epilepsies. METHODS: The targeted resequencing gene panel was designed using molecular inversion probe (MIP) capture technology and sequenced using massively parallel Illumina sequencing. RESULTS: We demonstrated proof of principle that mutations can be detected in 4 previously genotyped focal epilepsy cases. We searched for both germline and somatic mutations in 251 patients with unsolved sporadic or familial focal epilepsy and identified 11 novel or very rare missense variants in 5 different genes: CHRNA4, GRIN2B, KCNT1, PCDH19, and SCN1A. Of these, 2 were predicted to be pathogenic or likely pathogenic, explaining ∼0.8% of the cohort, and 8 were of uncertain significance based on available data. CONCLUSIONS: We have developed and validated a targeted resequencing panel for focal epilepsies, the most important clinical class of epilepsies, accounting for about 60% of all cases. Our application of MIP technology is an innovative approach that will be advantageous in the clinical setting because it is highly sensitive, efficient, and cost-effective for screening large patient cohorts. Our findings indicate that mutations in known genes likely explain only a small proportion of focal epilepsy cases. This is not surprising given the established clinical and genetic heterogeneity of these disorders and underscores the importance of further gene discovery studies in this complex syndrome.
OBJECTIVES: We report development of a targeted resequencing gene panel for focal epilepsy, the most prevalent phenotypic group of the epilepsies. METHODS: The targeted resequencing gene panel was designed using molecular inversion probe (MIP) capture technology and sequenced using massively parallel Illumina sequencing. RESULTS: We demonstrated proof of principle that mutations can be detected in 4 previously genotyped focal epilepsy cases. We searched for both germline and somatic mutations in 251 patients with unsolved sporadic or familial focal epilepsy and identified 11 novel or very rare missense variants in 5 different genes: CHRNA4, GRIN2B, KCNT1, PCDH19, and SCN1A. Of these, 2 were predicted to be pathogenic or likely pathogenic, explaining ∼0.8% of the cohort, and 8 were of uncertain significance based on available data. CONCLUSIONS: We have developed and validated a targeted resequencing panel for focal epilepsies, the most important clinical class of epilepsies, accounting for about 60% of all cases. Our application of MIP technology is an innovative approach that will be advantageous in the clinical setting because it is highly sensitive, efficient, and cost-effective for screening large patient cohorts. Our findings indicate that mutations in known genes likely explain only a small proportion of focal epilepsy cases. This is not surprising given the established clinical and genetic heterogeneity of these disorders and underscores the importance of further gene discovery studies in this complex syndrome.
Authors: Antonio Falace; Fabia Filipello; Veronica La Padula; Nicola Vanni; Francesca Madia; Davide De Pietri Tonelli; Fabrizio A de Falco; Pasquale Striano; Franca Dagna Bricarelli; Carlo Minetti; Fabio Benfenati; Anna Fassio; Federico Zara Journal: Am J Hum Genet Date: 2010-08-19 Impact factor: 11.025
Authors: Sarah E Heron; Katherine R Smith; Melanie Bahlo; Lino Nobili; Esther Kahana; Laura Licchetta; Karen L Oliver; Aziz Mazarib; Zaid Afawi; Amos Korczyn; Giuseppe Plazzi; Steven Petrou; Samuel F Berkovic; Ingrid E Scheffer; Leanne M Dibbens Journal: Nat Genet Date: 2012-10-21 Impact factor: 38.330
Authors: Joseph B Hiatt; Colin C Pritchard; Stephen J Salipante; Brian J O'Roak; Jay Shendure Journal: Genome Res Date: 2013-02-04 Impact factor: 9.043
Authors: Leanne M Dibbens; Boukje de Vries; Simona Donatello; Sarah E Heron; Bree L Hodgson; Satyan Chintawar; Douglas E Crompton; James N Hughes; Susannah T Bellows; Karl Martin Klein; Petra M C Callenbach; Mark A Corbett; Alison E Gardner; Sara Kivity; Xenia Iona; Brigid M Regan; Claudia M Weller; Denis Crimmins; Terence J O'Brien; Rosa Guerrero-López; John C Mulley; Francois Dubeau; Laura Licchetta; Francesca Bisulli; Patrick Cossette; Paul Q Thomas; Jozef Gecz; Jose Serratosa; Oebele F Brouwer; Frederick Andermann; Eva Andermann; Arn M J M van den Maagdenberg; Massimo Pandolfo; Samuel F Berkovic; Ingrid E Scheffer Journal: Nat Genet Date: 2013-03-31 Impact factor: 38.330
Authors: Michael S Hildebrand; Hans-Henrik M Dahl; John Anthony Damiano; Richard J H Smith; Ingrid E Scheffer; Samuel F Berkovic Journal: J Med Genet Date: 2013-03-06 Impact factor: 6.318
Authors: Gemma L Carvill; Sinéad B Heavin; Simone C Yendle; Jacinta M McMahon; Brian J O'Roak; Joseph Cook; Adiba Khan; Michael O Dorschner; Molly Weaver; Sophie Calvert; Stephen Malone; Geoffrey Wallace; Thorsten Stanley; Ann M E Bye; Andrew Bleasel; Katherine B Howell; Sara Kivity; Mark T Mackay; Victoria Rodriguez-Casero; Richard Webster; Amos Korczyn; Zaid Afawi; Nathanel Zelnick; Tally Lerman-Sagie; Dorit Lev; Rikke S Møller; Deepak Gill; Danielle M Andrade; Jeremy L Freeman; Lynette G Sadleir; Jay Shendure; Samuel F Berkovic; Ingrid E Scheffer; Heather C Mefford Journal: Nat Genet Date: 2013-05-26 Impact factor: 38.330
Authors: Sandra Jansen; Alexander Hoischen; Bradley P Coe; Gemma L Carvill; Hilde Van Esch; Daniëlle G M Bosch; Ulla A Andersen; Carl Baker; Marijke Bauters; Raphael A Bernier; Bregje W van Bon; Hedi L Claahsen-van der Grinten; Jozef Gecz; Christian Gilissen; Lucia Grillo; Anna Hackett; Tjitske Kleefstra; David Koolen; Malin Kvarnung; Martin J Larsen; Carlo Marcelis; Fiona McKenzie; Marie-Lorraine Monin; Caroline Nava; Janneke H Schuurs-Hoeijmakers; Rolph Pfundt; Marloes Steehouwer; Servi J C Stevens; Connie T Stumpel; Fleur Vansenne; Mirella Vinci; Maartje van de Vorst; Petra de Vries; Kali Witherspoon; Joris A Veltman; Han G Brunner; Heather C Mefford; Corrado Romano; Lisenka E L M Vissers; Evan E Eichler; Bert B A de Vries Journal: Eur J Hum Genet Date: 2017-12-05 Impact factor: 4.246
Authors: Juan A Moncayo; Ivan N Ayala; Jennifer M Argudo; Alex S Aguirre; Jashank Parwani; Ana Pachano; Diego Ojeda; Steven Cordova; Maria Gracia Mora; Christiany M Tapia; Juan Fernando Ortiz Journal: Cureus Date: 2022-06-10